Article Details
Retrieved on: 2021-04-08 13:59:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The FDA also extended the review period for Pfizer's supplemental NDA (sNDA) seeking approval of its marketed JAK inhibitor, Xeljanz for the treatment ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here